Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

49.23USD
20 Jan 2017
Change (% chg)

$-6.26 (-11.28%)
Prev Close
$55.49
Open
$50.01
Day's High
$50.69
Day's Low
$48.92
Volume
77,021,216
Avg. Vol
11,945,994
52-wk High
$77.12
52-wk Low
$48.92

Select another date:

Fri, Jan 20 2017

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK, Jan 20 Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve a patent litigation related to its cancer drug, Keytruda.

BRIEF-Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck

* Bristol-Myers Squibb and Ono Pharmaceutical Company enter settlement and license agreement with merck to resolve PD-1 antibody patent litigation

Bristol won't seek faster Opdivo/Yervoy lung cancer approval

Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer.

UPDATE 2-Bristol won't seek faster Opdivo/Yervoy lung cancer approval

Jan 19 Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer.

Bristol-Myers won't seek accelerated Opdivo lung cancer approval

Jan 19 Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer.

Select another date: